Literature DB >> 28161606

The absolute number of regulatory T cells in unmanipulated peripheral blood grafts predicts the occurrence of acute graft-versus-host disease post haplo-identical hematopoietic stem cell transplantation.

Li Ding1, Heng Zhu2, Yang Yang1, Hong-Min Yan1, Hai-Hong Zhang3, Dong-Mei Han1, Zhi-Dong Wang1, Xiao-Li Zheng1, Jing Liu1, Ling Zhu1, Zi-Kuan Guo4, Heng-Xiang Wang5.   

Abstract

CD4+CD25+Foxp3+ regulatory T cells (Tregs) have been reported to play a central role in suppressing acute graft-versus-host disease (aGVHD), but whether the Treg contents of grafts correlates with the occurrence of aGVHD post haplo-identical hematopoietic stem cell transplantation (haplo-HSCT) remains unclear. In the present study, changes in Tregs in peripheral blood (PB) were followed before and after granulocyte colony-stimulating factor (G-CSF) mobilization. In addition, functional analyses of Tregs in PB grafts and bone marrow (BM) grafts were performed. To probe the prognostic value of Tregs for aGVHD, an analysis of Tregs in haplo-identical grafts was conducted in 61 patients. Moreover, univariate and multivariate analyses of both clinical variables and cellular subsets were performed. The results showed that both the percentage Tregs of CD4+ T cells and absolute numbers of Tregs per 106 total nucleated cells significantly increased after G-CSF administration. Additionally, Tregs in PB grafts exhibited a stronger inhibitory effect on antigen-specific T cell proliferation than did Tregs in BM grafts. Strikingly, patients receiving more Tregs in PB grafts had a lower cumulative incidence of aGVHD II-IV (36% versus 58%, P=0.046). Further, in a multivariate analysis, the number of Tregs in PB grafts was significantly associated with a lower occurrence of aGVHD II-IV (P=0.02). In contrast, the number of Tregs in BM grafts was not associated with the occurrence of aGVHD in the current study. Further analysis showed that the Treg content in grafts did not affect Treg reconstitution, infection rate, or incidence of chronic GVHD after haplo-HSCT. Moreover, no significant correlations between cell types in grafts and the survival end points or relapse rates were found in the present study. In conclusion, our results suggest that a high number of Tregs in PB grafts is associated with reduced risk of aGVHD in haplo-HSCT in our transplant setting.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute graft versus host disease; Haplo-identical hematopoietic stem cell transplantation; Regulatory T cells

Mesh:

Substances:

Year:  2017        PMID: 28161606     DOI: 10.1016/j.leukres.2017.01.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Regulatory γδ T cells induced by G-CSF participate in acute graft-versus-host disease regulation in G-CSF-mobilized allogeneic peripheral blood stem cell transplantation.

Authors:  Li Xuan; Xiuli Wu; Dan Qiu; Li Gao; Hui Liu; Zhiping Fan; Fen Huang; Zhenyi Jin; Jing Sun; Yangqiu Li; Qifa Liu
Journal:  J Transl Med       Date:  2018-05-25       Impact factor: 5.531

2.  CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results.

Authors:  Amina Kariminia; Sabine Ivison; Bernard Ng; Jacob Rozmus; Susanna Sung; Avani Varshney; Mahmoud Aljurf; Sylvie Lachance; Irwin Walker; Cindy Toze; Jeff Lipton; Stephanie J Lee; Jeff Szer; Richard Doocey; Ian Lewis; Clayton Smith; Naeem Chaudhri; Megan K Levings; Raewyn Broady; Gerald Devins; David Szwajcer; Ronan Foley; Sara Mostafavi; Steven Pavletic; Donna A Wall; Stephan Couban; Tony Panzarella; Kirk R Schultz
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

3.  Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution.

Authors:  Katie Maurer; Haesook T Kim; Thomas M Kuczmarski; Heather M Garrity; Augustine Weber; Carol G Reynolds; Deborah Liney; Corey Cutler; Joseph H Antin; John Koreth; Jerome Ritz; Roman M Shapiro; Rizwan Romee; Catherine J Wu; Robert J Soiffer; Sarah Nikiforow; Vincent T Ho; Mahasweta Gooptu
Journal:  Blood Adv       Date:  2021-12-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.